Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas nejm.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nejm.org Daily Mail and Mail on Sunday newspapers.
Date Time
Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma
(From left) First and corresponding author Monika Metzger, M.D., Departments of Oncology and Global Pediatric Medicine; co- senior author Matthew Krasin, M.D., Department of Radiation Oncology; and co-senior author Melissa Hudson, M.D., Cancer Survivorship Division director.
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation exposures.
The study was the result of work by a multi-site consortium dedicated to pediatric Hodgkin-lymphoma. Collaborating institutions include St. Jude Children’s Research Hospital, Stanford University School of Medicine, Dana-Farber Cancer Institute, Massachusetts General Hospital, Maine Children’s Cancer P
VP&S Names 2021 Gerstner Scholars miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Treatment resistance in triple-negative breast cancers linked to softer tissue environment
Researchers at the University of California, San Francisco, have discovered that aggressive, triple-negative breast cancers (TNBCs) can evade treatment by reorganizing and softening the collagen matrix that surrounds the cancer cells. The study, which will be published April 2 in the
Journal of Experimental Medicine (
JEM), shows that the softer matrix activates a signaling pathway that promotes the cancer cells survival, and suggests that targeting this pathway could enhance the effectiveness of chemo- and radiotherapy in TNBC patients.
TNBC is an aggressive type of breast cancer with worse survival rates than other forms of the disease. Because TNBC cells lack the HER2 signaling receptor and the estrogen and progesterone hormone receptors, they cannot be eliminated by drugs that specifically target these proteins. Instead, TNBC patients are normally treated with a combination of surgery
March 2, 2021
The Office of Academic Integration (OVPAI) has awarded $750,000 in seed grants to 10 studies ranging from refugee health and legal rights, to a vaccine treating fentanyl addiction and overdose, to pancreatic cancer and antibiotic tolerance.
This year’s awardees represent faculty collaborations across five colleges and schools, and 18 departments and divisions across the Cornell Ithaca campus and Weill Cornell Medicine and Cornell Tech in New York City.
Designed to catalyze collaborative research interactions among Cornell faculty based in Ithaca and New York City, OVPAI provides funding opportunities that foster transdisciplinary, multi-investigator programs that aim to be competitive for support from federal funders and major foundations.